Bayesian Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Bayesian Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,480	Closed	-$84.1K	–	995
2022 Q4	$84.1K	Buy	2,480 +460	+23%	+$22.3K	0.01%	677
2022 Q3	$97K	Sell	2,020 -3,460	-63%	-$206K	0.02%	599
2022 Q2	$312K	Buy	+5,480	New	+$346K	0.06%	468
2021 Q2	–	Sell	-918	Closed	-$275K	–	568
2021 Q1	$275K	Sell	918 -257	-22%	-$80K	0.06%	368
2020 Q4	$300K	Buy	+1,175	New	+$304K	0.08%	305
2018 Q3	–	Sell	-867	Closed	-$635K	–	746
2018 Q2	$635K	Buy	867 +369	+74%	+$425K	0.14%	210
2018 Q1	$793K	Sell	498 -529	-52%	-$682K	0.2%	164
2017 Q4	$920K	Buy	+1,027	New	+$607K	0.19%	184
2017 Q2	–	Sell	-745	Closed	-$262K	–	544
2017 Q1	$262K	Sell	745 -868	-54%	-$195K	0.12%	283
2016 Q4	$297K	Buy	+1,613	New	+$328K	0.07%	430

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bayesian Capital Management's NKTR Position: Q1 2023 in Review

Bayesian Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 2,480 shares — an estimated $84.1K sold.

Bayesian Capital Management first reported a position in NKTR in Q4 2016 and held it in 10 quarters. The position peaked at $920K in Q4 2017. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

Bayesian Capital Management reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
Bayesian Capital Management sold 2,480 Nektar Therapeutics shares in Q1 2023, an estimated $84.1K.
Bayesian Capital Management first reported a position in Nektar Therapeutics in Q4 2016 and held it in 10 quarters.
Bayesian Capital Management's Nektar Therapeutics position peaked at $920K in Q4 2017.
194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Bayesian Capital Management's 13F filing for Q1 2023, filed 15 May 2023.